|
CA1327358C
(en)
|
1987-11-17 |
1994-03-01 |
Morio Fujiu |
Fluoro cytidine derivatives
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
WO1992022653A1
(en)
|
1991-06-14 |
1992-12-23 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
TW254946B
(da)
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
|
AU671491B2
(en)
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
|
PL181304B1
(pl)
|
1994-07-22 |
2001-07-31 |
Lilly Co Eli |
Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
|
|
US5476932A
(en)
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
DE69622183D1
(de)
|
1995-11-07 |
2002-08-08 |
Kirin Brewery |
Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
|
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
|
EP1117659B1
(en)
|
1998-09-29 |
2003-12-03 |
Wyeth Holdings Corporation |
Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
|
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
|
KR20020071931A
(ko)
|
2000-01-07 |
2002-09-13 |
트렌스폼 파마수티컬스 인코퍼레이티드 |
다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
|
|
US6384051B1
(en)
|
2000-03-13 |
2002-05-07 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
|
PT1318837E
(pt)
|
2000-08-11 |
2004-12-31 |
Wyeth Corp |
Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
|
|
TWI286074B
(en)
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
|
TWI296196B
(en)
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
|
IL157898A0
(en)
|
2001-04-06 |
2004-03-28 |
Wyeth Corp |
Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
|
|
TWI233359B
(en)
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
|
SG153647A1
(en)
|
2001-06-01 |
2009-07-29 |
Wyeth Corp |
Antineoplastic combinations
|
|
US20020198137A1
(en)
|
2001-06-01 |
2002-12-26 |
Wyeth |
Antineoplastic combinations
|
|
UA77200C2
(en)
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
|
KR20050044599A
(ko)
|
2001-11-27 |
2005-05-12 |
와이어쓰 홀딩스 코포레이션 |
Ｅｇｆ-ｒ 및 ｈｅｒ2 키나아제의 억제제로서의3-시아노퀴놀린
|
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
|
WO2003103676A2
(en)
|
2002-06-05 |
2003-12-18 |
Cedars-Sinai Medical Center |
Method of treating cancer using kinase inhibitors
|
|
WO2004004644A2
(en)
|
2002-07-05 |
2004-01-15 |
Beth Israel Deaconess Medical Center |
Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
|
|
US20040209930A1
(en)
|
2002-10-02 |
2004-10-21 |
Carboni Joan M. |
Synergistic methods and compositions for treating cancer
|
|
CL2004000016A1
(es)
|
2003-01-21 |
2005-04-15 |
Wyeth Corp |
Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
|
|
UA83484C2
(uk)
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
|
KR20060006058A
(ko)
|
2003-04-22 |
2006-01-18 |
와이어쓰 |
항신생물성 배합물
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
ES2297490T3
(es)
|
2003-07-23 |
2008-05-01 |
Bayer Pharmaceuticals Corporation |
Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
|
|
US20050025825A1
(en)
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
|
BRPI0413255A
(pt)
|
2003-08-01 |
2006-10-03 |
Wyeth Corp |
uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
|
|
MXPA06001590A
(es)
|
2003-08-19 |
2006-05-19 |
Wyeth Corp |
Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
|
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
|
AU2003304497B2
(en)
|
2003-09-15 |
2010-06-24 |
Wyeth Llc |
Substituted quinolines as protein tyrosine kinase enzyme inhibitors
|
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
|
US20050142192A1
(en)
|
2003-10-15 |
2005-06-30 |
Wyeth |
Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
|
|
CA2566823A1
(en)
|
2003-11-05 |
2005-05-19 |
Board Of Regents, The University Of Texas System |
Diagnostic and therapeutic methods and compositions involving pten and breast cancer
|
|
TW200526684A
(en)
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
|
AR047988A1
(es)
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
|
CN104774931B
(zh)
|
2004-03-31 |
2017-11-10 |
综合医院公司 |
测定癌症对表皮生长因子受体靶向性治疗反应性的方法
|
|
MX2007000944A
(es)
|
2004-07-23 |
2007-04-13 |
Astrazeneca Ab |
Metodo para pronosticar la sensibilidad de un tumor a farmacos del receptor erbb.
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
TW200616612A
(en)
|
2004-10-08 |
2006-06-01 |
Wyeth Corp |
Method for the teatment of polycystic kidney disease field of invention
|
|
TW200626610A
(en)
|
2004-10-13 |
2006-08-01 |
Wyeth Corp |
Analogs of 17-hydroxywortmannin as PI3K inhibitors
|
|
WO2006044748A2
(en)
|
2004-10-15 |
2006-04-27 |
Monogram Biosciences, Inc. |
RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
|
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
AU2006210572B2
(en)
|
2005-02-03 |
2011-08-04 |
The General Hospital Corporation |
Method for treating gefitinib resistant cancer
|
|
WO2006081985A1
(en)
|
2005-02-04 |
2006-08-10 |
F. Hoffmann-La Roche Ag |
Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
|
|
SI1859793T1
(sl)
|
2005-02-28 |
2011-08-31 |
Eisai R&D Man Co Ltd |
Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
|
|
WO2006098978A1
(en)
|
2005-03-09 |
2006-09-21 |
Abbott Laboratories |
Diagnostics method for identifying candidate patients for the treatment with trastuzumab
|
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
|
KR20080002826A
(ko)
|
2005-04-14 |
2008-01-04 |
와이어쓰 |
게피티니브 내성 환자에서의 표피 성장 인자 수용체（ｅｇｆｒ） 키나제 억제제의 용도
|
|
US20110045459A1
(en)
|
2005-04-21 |
2011-02-24 |
Mischel Paul S |
Molecular determinants of EGFR kinase inhibitor response in glioblastoma
|
|
ATE460937T1
(de)
|
2005-04-28 |
2010-04-15 |
Wyeth Corp |
Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
|
|
US20080193448A1
(en)
|
2005-05-12 |
2008-08-14 |
Pfizer Inc. |
Combinations and Methods of Using an Indolinone Compound
|
|
WO2006127205A2
(en)
|
2005-05-25 |
2006-11-30 |
Wyeth |
Methods of preparing 3-cyano-quinolines and intermediates made thereby
|
|
BRPI0610147A2
(pt)
|
2005-05-25 |
2010-06-01 |
Wyeth Corp |
método para preparar e sintetizar 3-cianoquinolinas substituìdas e 4-amino-3-cianoquinolinas
|
|
DE102005053679A1
(de)
|
2005-06-24 |
2006-12-28 |
Bayer Healthcare Ag |
Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
|
|
WO2007011619A2
(en)
|
2005-07-15 |
2007-01-25 |
Wyeth |
Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate
|
|
WO2007015569A1
(ja)
|
2005-08-01 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を予測する方法
|
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
|
CA2624613A1
(en)
|
2005-10-05 |
2007-04-12 |
Astrazeneca Uk Limited |
Method to predict or monitor the response of a patient to an erbb receptor drug
|
|
US20110052570A1
(en)
|
2005-10-26 |
2011-03-03 |
Children's Medical Center Corporation |
Method to prognose response to anti-egfr therapeutics
|
|
AU2006311877A1
(en)
|
2005-11-04 |
2007-05-18 |
Wyeth Llc |
Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
|
|
WO2007056117A1
(en)
|
2005-11-04 |
2007-05-18 |
Wyeth |
Antineoplastic combinations of temsirolimus and sunitinib malate
|
|
DK1948180T3
(da)
|
2005-11-11 |
2013-05-27 |
Boehringer Ingelheim Int |
Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
|
|
CN101312737B
(zh)
|
2005-11-24 |
2012-11-14 |
爱库里斯股份有限两合公司 |
副痘病毒与传统细胞毒性化疗剂联合作为治疗癌症的生化治疗
|
|
CA2632213A1
(en)
|
2005-12-22 |
2007-07-05 |
Wyeth |
Oral formulations comprising tigecycline
|
|
WO2007095038A2
(en)
|
2006-02-09 |
2007-08-23 |
Novartis Ag |
Mutations and polymorphisms of erbb2
|
|
TW200806282A
(en)
|
2006-05-05 |
2008-02-01 |
Wyeth Corp |
Solid dosage formulations
|
|
IL282783B2
(en)
|
2006-05-18 |
2023-09-01 |
Caris Mpi Inc |
A system and method for determining a personalized medical intervention for a disease stage
|
|
TW200808728A
(en)
|
2006-05-23 |
2008-02-16 |
Wyeth Corp |
Method of preparing 4-halogenated quinoline intermediates
|
|
EP2032989B2
(en)
|
2006-06-30 |
2015-10-28 |
Merck Sharp & Dohme Corp. |
Igfbp2 biomarker
|
|
ES2385613T3
(es)
|
2006-09-18 |
2012-07-27 |
Boehringer Ingelheim International Gmbh |
Método para tratar cánceres que portan mutaciones de EGFR
|
|
CA2664697A1
(en)
|
2006-09-28 |
2008-04-10 |
Follica, Inc. |
Methods, kits, and compositions for generating new hair follicles and growing hair
|
|
US20090317456A1
(en)
|
2006-10-13 |
2009-12-24 |
Medigene Ag |
Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
|
|
NZ578329A
(en)
|
2006-12-13 |
2012-05-25 |
Schering Corp |
Igf1r inhibitors for treating cancer
|
|
WO2008076257A2
(en)
|
2006-12-13 |
2008-06-26 |
Schering Corporation |
Treating cancer with anti-igflr antibody 19d12 = sch 717454
|
|
JP5406039B2
(ja)
|
2006-12-21 |
2014-02-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
|
|
CN101631536A
(zh)
|
2007-01-12 |
2010-01-20 |
惠氏公司 |
片中片组合物
|
|
CN104013956B
(zh)
|
2007-01-25 |
2018-12-18 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
|
ES2639854T3
(es)
|
2007-02-01 |
2017-10-30 |
Takeda Pharmaceutical Company Limited |
Preparación de comprimidos sin causar problemas de fabricación de comprimidos
|
|
WO2008121467A2
(en)
|
2007-02-28 |
2008-10-09 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for treating cancer
|
|
GB0706633D0
(en)
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
|
US8715665B2
(en)
|
2007-04-13 |
2014-05-06 |
The General Hospital Corporation |
Methods for treating cancer resistant to ErbB therapeutics
|
|
CA2684265A1
(en)
|
2007-04-19 |
2008-10-30 |
Wellstat Biologics Corporation |
Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment
|
|
WO2008136838A1
(en)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
|
US20110014117A1
(en)
|
2007-06-28 |
2011-01-20 |
Schering Corporation |
Anti-igf1r
|
|
ES2569215T3
(es)
|
2007-09-10 |
2016-05-09 |
Boston Biomedical, Inc. |
Un nuevo grupo de inhibidores de la ruta de Stat3 e inhibidores de la ruta de las células madre del cáncer
|
|
WO2009042613A1
(en)
|
2007-09-24 |
2009-04-02 |
Tragara Pharmaceuticals, Inc. |
Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
CN101918579A
(zh)
|
2007-10-22 |
2010-12-15 |
先灵公司 |
完全人抗-vegf抗体和使用方法
|
|
JP2011502571A
(ja)
|
2007-11-05 |
2011-01-27 |
ピュアテック ベンチャーズ |
医薬化合物を投与するための方法、キット、および組成物
|
|
MX2010006854A
(es)
|
2007-12-18 |
2010-09-09 |
Schering Corp |
Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
|
|
US20100297118A1
(en)
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
|
WO2009105234A2
(en)
|
2008-02-19 |
2009-08-27 |
Combinatorx, Incorporated |
Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
|
|
CA2716826C
(en)
|
2008-02-25 |
2017-05-09 |
Prometheus Laboratories Inc. |
Drug selection for breast cancer therapy using antibody-based arrays
|
|
WO2009111073A2
(en)
|
2008-03-06 |
2009-09-11 |
Odyssey Thera, Inc. |
High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
|
|
EP2259797A2
(en)
|
2008-03-25 |
2010-12-15 |
Schering Corporation |
Methods for treating or preventing colorectal cancer
|
|
EP2279267A4
(en)
|
2008-03-27 |
2012-01-18 |
Vascular Biosciences Inc |
METHOD FOR IDENTIFICATION OF NEW THERAPEUTIC CANDIDATES VIA GENE EXPRESSION ANALYSIS IN VASCULAR DISEASES
|
|
US20090246198A1
(en)
|
2008-03-31 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
US20110182888A1
(en)
|
2008-04-08 |
2011-07-28 |
Peter Ordentlich |
Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
|
|
TW201004627A
(en)
|
2008-04-18 |
2010-02-01 |
Reata Pharmaceuticals Inc |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
|
JP5564490B2
(ja)
|
2008-04-18 |
2014-07-30 |
リアタ ファーマシューティカルズ インコーポレイテッド |
抗炎症性ファルマコアを含む化合物および使用法
|
|
NZ588710A
(en)
|
2008-04-18 |
2012-12-21 |
Reata Pharmaceuticals Inc |
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
|
|
CN104250280A
(zh)
|
2008-04-18 |
2014-12-31 |
里亚塔医药公司 |
抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
|
|
WO2009129545A1
(en)
|
2008-04-18 |
2009-10-22 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
|
|
MX2010012064A
(es)
|
2008-05-05 |
2010-12-06 |
Schering Corp |
Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
|
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
|
KR20180128078A
(ko)
|
2008-06-17 |
2018-11-30 |
와이어쓰 엘엘씨 |
Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
|
|
JP5758801B2
(ja)
|
2008-07-22 |
2015-08-05 |
トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓ ｏｆ Ｄａｒｔｍｏｕｔｈ Ｃｏｌｌｅｇｅ |
単環式シアノエノンおよびその使用方法説明
|
|
NZ590464A
(en)
|
2008-08-04 |
2012-10-26 |
Wyeth Llc |
Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
|
|
US20100069340A1
(en)
|
2008-09-11 |
2010-03-18 |
Wyeth |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
|
EP3075864A1
(en)
|
2008-10-14 |
2016-10-05 |
Caris MPI, Inc. |
Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
|
|
WO2010048477A2
(en)
|
2008-10-24 |
2010-04-29 |
Wyeth Llc |
Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
|
|
CN102223886A
(zh)
|
2008-11-07 |
2011-10-19 |
安龙制药公司 |
Erbb-3(her3)选择性组合疗法
|
|
WO2010085845A1
(en)
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
|
AU2010210636A1
(en)
|
2009-02-04 |
2011-09-22 |
Bipar Sciences, Inc. |
Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
|
|
WO2010098627A2
(ko)
|
2009-02-27 |
2010-09-02 |
한올바이오파마주식회사 |
약제학적 제제
|
|
US9073916B2
(en)
|
2009-03-11 |
2015-07-07 |
Auckland Uniservices Limited |
Prodrug forms of kinase inhibitors and their use in therapy
|
|
HUE061640T2
(hu)
|
2009-04-06 |
2023-07-28 |
Wyeth Llc |
Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával
|
|
AR076053A1
(es)
|
2009-04-14 |
2011-05-18 |
Schering Corp |
Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
|
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
ES2659725T3
(es)
|
2009-05-05 |
2018-03-19 |
Dana-Farber Cancer Institute, Inc. |
Inhibidores de EGFR y procedimiento de tratamiento de trastornos
|
|
CN102470109A
(zh)
|
2009-07-02 |
2012-05-23 |
惠氏有限责任公司 |
3-氰基喹啉片剂制剂及其应用
|
|
KR20110007985A
(ko)
|
2009-07-17 |
2011-01-25 |
한올바이오파마주식회사 |
Ｎ,ｎ―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
|
WO2011008053A2
(ko)
|
2009-07-17 |
2011-01-20 |
한올바이오파마주식회사 |
Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
|
KR101211227B1
(ko)
|
2009-08-25 |
2012-12-11 |
한올바이오파마주식회사 |
메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
KR20110021691A
(ko)
|
2009-08-25 |
2011-03-04 |
한올바이오파마주식회사 |
메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
WO2011025269A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
WO2011038467A1
(en)
|
2009-10-01 |
2011-04-07 |
Csl Limited |
Method of treatment of philadelphia chromosome positive leukaemia
|
|
PT2498756T
(pt)
|
2009-11-09 |
2019-11-26 |
Wyeth Llc |
Formulações de comprimidos de maleato de neratinib
|
|
CN107441058A
(zh)
|
2009-11-09 |
2017-12-08 |
惠氏有限责任公司 |
包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
|
|
EP2896632B1
(en)
|
2009-11-13 |
2017-10-25 |
Daiichi Sankyo Europe GmbH |
Material and methods for treating or preventing HER-3 associated diseases
|
|
US20130012465A1
(en)
|
2009-12-07 |
2013-01-10 |
Boehringer Ingelheim International Gmbh |
Bibw 2992 for use in the treatment of triple negative breast cancer
|
|
EP2510121A1
(en)
|
2009-12-11 |
2012-10-17 |
Wyeth LLC |
Phosphatidylinositol-3-kinase pathway biomarkers
|
|
US8338456B2
(en)
|
2010-01-13 |
2012-12-25 |
Wyeth Llc |
Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor
|